Nuvectis PharmaNVCT
13F holders, Q3 2024 (September 30)At the end of Q3 2024, 31 institutions reported holding Nuvectis Pharma Inc. (NVCT) in their 13F filings, down 10 from Q2 2024. 3 opened new positions and 13 sold out. The largest holders were Vanguard Group Inc. ($1.9M), Baldwin Wealth Partners LLC ($1.1M) and Geode Capital Management, LLC ($501K). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Nuvectis Pharma Inc.
- CUSIP
- 67080T108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $578K |
| Exits | 13 | $1.0M |
All 13F filers, Q2 2024 → Q3 2024: 217,750 shares bought and 339,594 shares sold, net −121,844 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 31 holders
| Vanguard Group Inc. | 0.00% | Add +19.9% | 301,138 | $1.9M |
| Baldwin Wealth Partners LLC | 0.07% | Add +3.3% | 174,130 | $1.1M |
| Geode Capital Management, LLC | 0.00% | Add +49.8% | 79,716 | $501K |
| Millennium Management | 0.00% | Reduce -42.7% | 68,499 | $431K |
| Iridian Asset Management LLC | 0.07% | New | 55,380 | $348K |
| Gsa Capital Partners LLP | 0.02% | Add +3.7% | 50,129 | $315K |
| BlackRock, Inc. | 0.00% | — | 49,554 | $312K |
| Forbes J M & Co. LLP | 0.03% | Add +2.1% | 48,401 | $304K |
| Marshall Wace, LLP | 0.00% | Add +26.4% | 42,814 | $269K |
| Two Sigma Investments, LP | 0.00% | Add +105.3% | 26,785 | $168K |
| Susquehanna International Group, LLP | 0.00% | New | 26,463 | $166K |
| Qube Research & Technologies Ltd | 0.00% | Add +181.2% | 22,433 | $141K |
| Edmond DE Rothschild Holding S.A. | 0.00% | No change | 19,170 | $121K |
| Renaissance Technologies | 0.00% | Reduce -78.8% | 15,800 | $99K |
| State Street Corp. | 0.00% | No change | 15,300 | $96K |
| Northern Trust Corp. | 0.00% | Reduce -69.4% | 15,253 | $96K |
| Baxter Bros Inc. | 0.01% | No change | 12,500 | $79K |
| Nations Financial Group Inc, /Ia/ | 0.00% | New | 10,000 | $63K |
| Citigroup Inc. | 0.00% | Add +82.0% | 8,887 | $56K |
| Morgan Stanley | 0.00% | Reduce -77.0% | 2,348 | $15K |
| Barclays PLC | 0.00% | Reduce -86.2% | 1,144 | $7K |
| Catalyst Funds Management Pty Ltd | 0.00% | No change | 900 | $6K |
| Bank of America Corp. | 0.00% | Reduce -0.5% | 760 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -90.2% | 588 | $4K |
| FMR LLC | 0.00% | Reduce -58.6% | 402 | $3K |
| Hollencrest Capital Management | 0.00% | No change | 280 | $2K |
| JPMorgan Chase & Co. | 0.00% | Reduce -98.7% | 192 | $1K |
| Lanark Financial, Inc. | 0.00% | No change | 300 | $1K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 100 | $629 |
| Nisa Investment Advisors, LLC | 0.00% | Reduce -94.3% | 12 | $75 |
| UBS Group AG | 0.00% | Reduce -15.4% | 11 | $69 |
"% of holder's portfolio" is NVCT's weight in each manager's 13F, not the share of Nuvectis Pharma Inc. the manager owns.